Screener
BioCryst Pharmaceuticals BCRX Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest income | (2,434) | (2,516) | (4,690) | (5,540) |
| Interest expense | 21,712 | 21,582 | 41,491 | 45,076 |
| Foreign currency (gains) losses | (27) | 63 | 198 | 62 |
| Loss on extinguishment of debt | — | 4,171 | — | 4,171 |
| Other (income) expense, net | (260) | — | 1,202 | — |
| Income tax expense | 1,079 | 1,401 | 2,083 | 2,127 |
| Consolidated net income (loss) | $78,395 | $5,085 | $(643,417) | $5,117 |
| 1 The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's business segments — income tax?
- BioCryst Pharmaceuticals (BCRX) reported business segments — income tax of $1.08M in Q2 2026.
- How has BioCryst Pharmaceuticals's business segments — income tax changed year-over-year?
- BioCryst Pharmaceuticals's business segments — income tax decreased by 23.0% year-over-year, from $1.4M to $1.08M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — income tax?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — income tax has grown at a 8.9% compound annual growth rate (CAGR), from $2.73M to $3.53M.
- What does business segments — income tax mean?
- Represents the total tax liability incurred by the business segment based on its taxable income for the reporting period. This metric reflects the impact of jurisdictional tax regulations on the segment's bottom-line performance.
Ask your AI about BioCryst Pharmaceuticals's business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude